ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N -acetylcysteine for first-episode psychosis
This study has the potential to offer a new, safe, and efficacious treatment for people with FEP, leading to better treatment outcomes. Additionally, the neuroprotective dimension of this study may lead to a better long-term prognosis for people with FEP. It has the potential to uncover a novel treatment that targets the neurobiological mechanisms of FEP and, if successful, will be a major advance for psychiatry.Trial registrationAustralian New Zealand Clinical Trials Registry, ID: ACTRN12618000413224. Registered on 21 March 2018.
Source: Trials - Category: Research Source Type: clinical trials
More News: Acetylcysteine | Antidoxidants | Australia Health | Bipolar | Brain | Clinical Trials | Mania | Neurology | New Zealand Health | Psychiatry | Research | Schizophrenia | Study